ACXP News and Press, Acurx Pharmaceuticals Inc. From 10/09/23

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is one of today's top gainers. The company's shares are currently up 42.08% on the day to $2.73. Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate...

2023-10-03 10:00:05 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...

2023-10-03 08:21:17 ET More on Neptune Wellness Solutions, Vipshop, etc. Vipshop's Strong Results Overshadowed By Troubling Outlook Vipshop Holdings Limited (VIPS) Q2 2023 Earnings Call Transcript WeWork Inc. (WE) Q2 2023 Earnings Call Transcript WeWork skips...

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection PR Newswire Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat ...

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress PR Newswire ...

Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023 PR Newswire STATEN ISLAND, N.Y. , Aug. 22, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinica...

2023-08-14 13:18:02 ET Acurx Pharmaceuticals, Inc. (ACXP) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Rob Shawah - CFO Dave Luci - President and CEO Conference Call Participants Ed Arce - HC. Wainwright Michael Oku...

2023-08-14 11:30:17 ET Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q2 GAAP EPS of -$0.28. The Company ended the second quarter with cash totaling $9.1 million compared to $9.1 million as of December 31, 2022. For further details see: Acurx Pharmaceutica...

2023-08-14 07:25:38 ET Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q2 GAAP EPS of -$0.28 misses by $0.07 . The company ended the second quarter with cash totaling $9.1 million compared to $9.1 million as of December 31, 2022. For further details see: ...

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Aug. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage bio...